• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PXS
Click for more information
0.00% 8.5¢

PHARMAXIS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PXSFinal Director's Interest Notice01/05/12
PXSPharmaxis Appoints New Chairman01/05/12
PXSInvestor Presentation27/04/12
PXSPharmaxis Receives Approval to Market Bronchitol in the EUPRICE SENSITIVE20/04/12
PXSPharmaxis Quarterly Report to Shareholders March 201218/04/12
PXSAppendix 4C - quarterlyPRICE SENSITIVE18/04/12
PXSPharmaxis Quarterly Investor Conference Call17/04/12
PXSPXS Completes Phase II study with ASM8 in asthma patientsPRICE SENSITIVE17/04/12
PXSBecoming a substantial holder17/04/12
PXSCeasing to be a substantial holder13/04/12
PXSBecoming a substantial holder11/04/12
PXSPharmaxis Announces Agreement for EU Supply of BronchitolPRICE SENSITIVE29/03/12
PXSEuropean Regulatiry Update on BronchitolPRICE SENSITIVE16/03/12
PXSBronchitol to be Reimbursed in AustraliaPRICE SENSITIVE14/03/12
PXSChange of Director's Interest Notice27/02/12
PXSHalf Yearly Report and AccountsPRICE SENSITIVE03/02/12
PXSAppendix 4C - quarterlyPRICE SENSITIVE24/01/12
PXSQuarterly Report to Shareholders24/01/12
PXSQuarterly Investor Conference Call23/01/12
PXSChange of Director's Interest Notice30/12/11
PXSBecoming a substantial holder22/12/11
PXSPharmaxis Files PBAC Minor Resubmission for BronchitolPRICE SENSITIVE20/12/11
PXSChange of Director's Interest Notice - D Hanley16/12/11
PXSChange of Director's Interest Notice - J Villiger16/12/11
PXSChange of Director's Interest Notice - Delaat16/12/11
PXSAppendix 3B - Exercise of Employee Options16/12/11
PXSAppendix 3B - Rights Offering Second Settlement16/12/11
PXSPhase 3 Trial in Bronchiectasis Reaches Recruitment TargetPRICE SENSITIVE13/12/11
PXSResults of Retail Entitlement Offer13/12/11
PXSAppendix 3B29/11/11
PXSChange of Director's Interest Notice25/11/11
PXSEntitlement Offer - Letter to Ineligible Shareholders24/11/11
PXSRetail Offer BookletPRICE SENSITIVE24/11/11
PXSResults of Meeting22/11/11
PXSCEO Presentation to 2011 AGM21/11/11
PXSChairman's Address 2011 AGM21/11/11
PXSInstitutional Component of Entitlement OfferPRICE SENSITIVE18/11/11
PXSASX Circular - Entitlement Offer16/11/11
PXSAppendix 3B16/11/11
PXSNotice under section 708AA(2)(f)16/11/11
PXSCapital Raising Presentation16/11/11
PXSProRata Entitlement Offer to Raise up to Approximately $80m16/11/11
PXSTrading HaltPRICE SENSITIVE16/11/11
PXSPharmaxis Announces PBAC Decision on BronchitolPRICE SENSITIVE09/11/11
PXSInvestor Presentation25/10/11
PXSReinstatement to Official QuotationPRICE SENSITIVE24/10/11
PXSPharmaxis Announces Positive Bronchitol Opinion for EuropePRICE SENSITIVE24/10/11
PXSInvestor Conference Call - Bronchitol EU Re-examination21/10/11
PXSSuspension from Official QuotationPRICE SENSITIVE20/10/11
PXSTrading HaltPRICE SENSITIVE17/10/11
PXSNotice of 2011 Annual General Meeting/Proxy Form17/10/11
PXSAppendix 4C - quarterlyPRICE SENSITIVE12/10/11
PXSQuarterly Report to Shareholders - September 201112/10/11
PXSQuarterly Investor Conference Call11/10/11
PXSChange in substantial holding10/10/11
PXS2011 Annual Report to Shareholders29/09/11
PXSPhase II Trial in Allergic Asthma Completes RecruitmentPRICE SENSITIVE29/09/11
PXSUpdate on EU Bronchitol Marketing ApplicationPRICE SENSITIVE28/09/11
PXSChange of Director's Interest Notice27/09/11
PXSShare Trading Policy26/09/11
PXSAppendix 3B - Employee Share Plan30/08/11
PXSChange of Director's Interest Notice26/08/11
PXSAppendix 3B - Exercise of Employee Options26/08/11
PXSCeasing to be a substantial holder22/08/11
PXSRe-examination Documents Filed for EU Bronchitol ApplicationPRICE SENSITIVE22/08/11
PXSPreliminary Final ReportPRICE SENSITIVE12/08/11
PXSChange of Director's Interest Notice08/08/11
PXSAppendix 3B exercise of options04/08/11
PXSJune 2011 Quarterly Report to Shareholders20/07/11
PXSAppendix 4C - quarterlyPRICE SENSITIVE20/07/11
PXSQuarterly Investor Conference Call19/07/11
PXSBronchitol Resubmitted to Australian PBACPRICE SENSITIVE12/07/11
PXSRe-examination of Bronchitol Marketing Application RequestedPRICE SENSITIVE05/07/11
PXSUpdated Investor Presentation29/06/11
PXSChange of Director's Interest Notice28/06/11
PXSEU Marketing Authorisation Application Review of BronchitolPRICE SENSITIVE27/06/11
PXSEU CHMP Confirms Negative Trend Vote on BronchitolPRICE SENSITIVE24/06/11
PXSChange in substantial holding21/06/11
PXSChange in substantial holding16/06/11
PXSResponse to ASX Query LetterPRICE SENSITIVE31/05/11
PXSChange of Director's Interest Notice27/05/11
PXSChange in substantial holding27/05/11
PXSCeasing to be a substantial holder26/05/11
PXSPharmaxis Receives Negative Bronchitol Trend Vote from CHMPPRICE SENSITIVE25/05/11
PXSAdditional Background to Appendix 3Y Filed 18 May 201124/05/11
PXSInvestor Conference Call24/05/11
PXSTrading HaltPRICE SENSITIVE23/05/11
PXSChange of Director's Interest Notice18/05/11
PXSAppendix 3B: Exercise of Employee Options27/04/11
PXSAppendix 3B - Exercise of Employee Options21/04/11
PXSBronchitol Deferred by Australian PBACPRICE SENSITIVE21/04/11
PXSAppendix 4C - quarterlyPRICE SENSITIVE13/04/11
PXSQuarterly Report to Shareholders - March 201113/04/11
PXSQuarterly Investor Conference Call12/04/11
PXSBecoming a substantial holder16/03/11
PXSBecoming a substantial holder03/03/11
PXSCeasing to be a substantial holder14/02/11
PXSAustralian TGA Approves Bronchitol for Cystic FibrosisPRICE SENSITIVE08/02/11
PXSHalf Yearly Report and AccountsPRICE SENSITIVE04/02/11
PXSAppendix 4C - quarterlyPRICE SENSITIVE25/01/11
PXSFinal Director's Interest Notice
01/05/12
PXSPharmaxis Appoints New Chairman
01/05/12
PXSInvestor Presentation
27/04/12
PXSPharmaxis Receives Approval to Market Bronchitol in the EU
20/04/12PRICE SENSITIVE
PXSPharmaxis Quarterly Report to Shareholders March 2012
18/04/12
PXSAppendix 4C - quarterly
18/04/12PRICE SENSITIVE
PXSPharmaxis Quarterly Investor Conference Call
17/04/12
PXSPXS Completes Phase II study with ASM8 in asthma patients
17/04/12PRICE SENSITIVE
PXSBecoming a substantial holder
17/04/12
PXSCeasing to be a substantial holder
13/04/12
PXSBecoming a substantial holder
11/04/12
PXSPharmaxis Announces Agreement for EU Supply of Bronchitol
29/03/12PRICE SENSITIVE
PXSEuropean Regulatiry Update on Bronchitol
16/03/12PRICE SENSITIVE
PXSBronchitol to be Reimbursed in Australia
14/03/12PRICE SENSITIVE
PXSChange of Director's Interest Notice
27/02/12
PXSHalf Yearly Report and Accounts
03/02/12PRICE SENSITIVE
PXSAppendix 4C - quarterly
24/01/12PRICE SENSITIVE
PXSQuarterly Report to Shareholders
24/01/12
PXSQuarterly Investor Conference Call
23/01/12
PXSChange of Director's Interest Notice
30/12/11
PXSBecoming a substantial holder
22/12/11
PXSPharmaxis Files PBAC Minor Resubmission for Bronchitol
20/12/11PRICE SENSITIVE
PXSChange of Director's Interest Notice - D Hanley
16/12/11
PXSChange of Director's Interest Notice - J Villiger
16/12/11
PXSChange of Director's Interest Notice - Delaat
16/12/11
PXSAppendix 3B - Exercise of Employee Options
16/12/11
PXSAppendix 3B - Rights Offering Second Settlement
16/12/11
PXSPhase 3 Trial in Bronchiectasis Reaches Recruitment Target
13/12/11PRICE SENSITIVE
PXSResults of Retail Entitlement Offer
13/12/11
PXSAppendix 3B
29/11/11
PXSChange of Director's Interest Notice
25/11/11
PXSEntitlement Offer - Letter to Ineligible Shareholders
24/11/11
PXSRetail Offer Booklet
24/11/11PRICE SENSITIVE
PXSResults of Meeting
22/11/11
PXSCEO Presentation to 2011 AGM
21/11/11
PXSChairman's Address 2011 AGM
21/11/11
PXSInstitutional Component of Entitlement Offer
18/11/11PRICE SENSITIVE
PXSASX Circular - Entitlement Offer
16/11/11
PXSAppendix 3B
16/11/11
PXSNotice under section 708AA(2)(f)
16/11/11
PXSCapital Raising Presentation
16/11/11
PXSProRata Entitlement Offer to Raise up to Approximately $80m
16/11/11
PXSTrading Halt
16/11/11PRICE SENSITIVE
PXSPharmaxis Announces PBAC Decision on Bronchitol
09/11/11PRICE SENSITIVE
PXSInvestor Presentation
25/10/11
PXSReinstatement to Official Quotation
24/10/11PRICE SENSITIVE
PXSPharmaxis Announces Positive Bronchitol Opinion for Europe
24/10/11PRICE SENSITIVE
PXSInvestor Conference Call - Bronchitol EU Re-examination
21/10/11
PXSSuspension from Official Quotation
20/10/11PRICE SENSITIVE
PXSTrading Halt
17/10/11PRICE SENSITIVE
PXSNotice of 2011 Annual General Meeting/Proxy Form
17/10/11
PXSAppendix 4C - quarterly
12/10/11PRICE SENSITIVE
PXSQuarterly Report to Shareholders - September 2011
12/10/11
PXSQuarterly Investor Conference Call
11/10/11
PXSChange in substantial holding
10/10/11
PXS2011 Annual Report to Shareholders
29/09/11
PXSPhase II Trial in Allergic Asthma Completes Recruitment
29/09/11PRICE SENSITIVE
PXSUpdate on EU Bronchitol Marketing Application
28/09/11PRICE SENSITIVE
PXSChange of Director's Interest Notice
27/09/11
PXSShare Trading Policy
26/09/11
PXSAppendix 3B - Employee Share Plan
30/08/11
PXSChange of Director's Interest Notice
26/08/11
PXSAppendix 3B - Exercise of Employee Options
26/08/11
PXSCeasing to be a substantial holder
22/08/11
PXSRe-examination Documents Filed for EU Bronchitol Application
22/08/11PRICE SENSITIVE
PXSPreliminary Final Report
12/08/11PRICE SENSITIVE
PXSChange of Director's Interest Notice
08/08/11
PXSAppendix 3B exercise of options
04/08/11
PXSJune 2011 Quarterly Report to Shareholders
20/07/11
PXSAppendix 4C - quarterly
20/07/11PRICE SENSITIVE
PXSQuarterly Investor Conference Call
19/07/11
PXSBronchitol Resubmitted to Australian PBAC
12/07/11PRICE SENSITIVE
PXSRe-examination of Bronchitol Marketing Application Requested
05/07/11PRICE SENSITIVE
PXSUpdated Investor Presentation
29/06/11
PXSChange of Director's Interest Notice
28/06/11
PXSEU Marketing Authorisation Application Review of Bronchitol
27/06/11PRICE SENSITIVE
PXSEU CHMP Confirms Negative Trend Vote on Bronchitol
24/06/11PRICE SENSITIVE
PXSChange in substantial holding
21/06/11
PXSChange in substantial holding
16/06/11
PXSResponse to ASX Query Letter
31/05/11PRICE SENSITIVE
PXSChange of Director's Interest Notice
27/05/11
PXSChange in substantial holding
27/05/11
PXSCeasing to be a substantial holder
26/05/11
PXSPharmaxis Receives Negative Bronchitol Trend Vote from CHMP
25/05/11PRICE SENSITIVE
PXSAdditional Background to Appendix 3Y Filed 18 May 2011
24/05/11
PXSInvestor Conference Call
24/05/11
PXSTrading Halt
23/05/11PRICE SENSITIVE
PXSChange of Director's Interest Notice
18/05/11
PXSAppendix 3B: Exercise of Employee Options
27/04/11
PXSAppendix 3B - Exercise of Employee Options
21/04/11
PXSBronchitol Deferred by Australian PBAC
21/04/11PRICE SENSITIVE
PXSAppendix 4C - quarterly
13/04/11PRICE SENSITIVE
PXSQuarterly Report to Shareholders - March 2011
13/04/11
PXSQuarterly Investor Conference Call
12/04/11
PXSBecoming a substantial holder
16/03/11
PXSBecoming a substantial holder
03/03/11
PXSCeasing to be a substantial holder
14/02/11
PXSAustralian TGA Approves Bronchitol for Cystic Fibrosis
08/02/11PRICE SENSITIVE
PXSHalf Yearly Report and Accounts
04/02/11PRICE SENSITIVE
PXSAppendix 4C - quarterly
25/01/11PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
Resolute shares bounce back as second payment made to Mali government to secure workers' release Resolute Mining Ltd has told investors that a second payment has been made to the Mali government following the detention of three employees
Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher Vitrafy Life Sciences Limited (ASX:VFY) has defied this month’s odds to become the only newly-listed Australian company to survive a surprisingly rough November (for newcomers, at least) without sagging below its IPO price.The cryopreservation biotech did give some back on Friday,...
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
HotCopper Highlights: Your most watched stocks for Week 48, 2024 Good afternoon, a happy end of the week, and welcome to HotCopper Highlights – I’m Jonathon Davidson. Let’s get into it.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.